Enlivex Therapeutics Ltd. Annual Share-based Payment Arrangement, Expense in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Enlivex Therapeutics Ltd. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2020 to 2023.
  • Enlivex Therapeutics Ltd. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $388K, a 24.1% decline year-over-year.
  • Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2023 was $1.95M, a 28.1% decline from 2022.
  • Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2022 was $2.71M, a 6.93% decline from 2021.
  • Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2021 was $2.91M, a 116% increase from 2020.
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $1.95M -$761K -28.1% Jan 1, 2023 Dec 31, 2023 20-F 2024-04-30
2022 $2.71M -$202K -6.93% Jan 1, 2022 Dec 31, 2022 20-F 2024-04-30
2021 $2.91M +$1.57M +116% Jan 1, 2021 Dec 31, 2021 20-F 2024-04-30
2020 $1.35M Jan 1, 2020 Dec 31, 2020 20-F 2022-04-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.